HCP 01
Medical Oncologist · Germany · Senior consultant
Illustrative synthetic data for prototype demonstration — not real clinical findings.
Discussion summary
Academic centre lead with a high HR+/HER2- caseload; data-driven and generally an early adopter where benefit is clear.
Key themes
Pre / post perception
Overall perception shiftPre-congress vs post-congress
4 improved
Perception of clinical efficacy
Confidence in the evidence
Safety / tolerability perception
Likelihood to prescribe
Familiarity with treatment
Competitive perception
Illustrative synthetic measures. Movement is shown as an observed pre/post shift, not a causal effect of the congress.
KBQs discussed
Position against each predefined questionClinical significance of the primary endpoint
What is the expert consensus regarding the clinical significance of the study’s primary endpoint results?
“The effect size here is hard to ignore — for the patients I see this is a genuinely meaningful result.”
Safety, tolerability and willingness to prescribe
How do HCP perceptions of the trial’s safety and tolerability profile impact their willingness to adopt and prescribe the treatment?
“The tolerability is manageable in my hands — I would prescribe this without much hesitation.”
Use in node-positive populations
What is the clinical consensus among HCPs regarding the use of CDK4/6 inhibitors in node-positive patient populations?
“In node-positive patients with higher recurrence risk, the case for treating is strong.”
Sequencing after adjuvant recurrence
How do clinicians approach treatment sequencing following recurrence on an adjuvant CDK4/6 inhibitor?
“Progression on the class tells me the mechanism is exhausted — I switch rather than persist.”
Compelling nature of the primary endpoint
How compelling are the primary endpoint findings in driving prospective prescribers to select this treatment over existing options?
“It is a welcome result, but on its own it does not yet displace what I use first.”
Perception of safety and tolerability
How do experts perceive the safety and tolerability profile demonstrated in the trial?
“The profile is predictable and consistent with the class — nothing here surprises me.”